Use of Acetyl Salicylic Acid and Terbutalin in Assisted Reproductive Techniques (ART)

• Sponsor: Sykehuset Telemark (Other)
• Overall Status: Completed
• CT.gov ID: NCT00518141
• Collaborator: (none)
• Enrollment: 300
• Location: 1
• Arms: 6
• Duration (Months): 38
• Patients Per Site Per Month: 7.9

Study Details

Study Description

Brief Summary

This study aims to determine the possible effects of Acetyl Salicylic Acid (ASA) and Terbutalin on ART treatment.

Condition or Disease	Intervention/Treatment	Phase
Reproductive Techniques, Assisted	Drug: Acetyl Salicylic Acid and Terbutalin	N/A

Detailed Description

This study aims to determine the possible effects of ASA and Terbutalin on ART treatment.

Study Design

• Study Type: Interventional
• Actual Enrollment: 300 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Use of Acetylsalicylic Acid and Terbutalin in ART
• Study Start Date: Mar 1, 2006
• Actual Primary Completion Date: May 1, 2009
• Actual Study Completion Date: May 1, 2009

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 1 FER	Drug: Acetyl Salicylic Acid and Terbutalin; ASA 75 mg, Terbutalin 5mg
No Intervention: 2 FER
Experimental: 3 SET	Drug: Acetyl Salicylic Acid and Terbutalin; ASA 75 mg, Terbutalin 5mg
No Intervention: 4 SET
Experimental: 5 DET	Drug: Acetyl Salicylic Acid and Terbutalin; ASA 75 mg, Terbutalin 5mg
No Intervention: 6 DET

Outcome Measures

Primary Outcome Measures

1. Pregnancy [7 weeks]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 39 Years
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Infertile women below 39 years of age

Exclusion Criteria:

• Women who may react allergically to the drugs administered

• Women with hyperthyroid or IDDM

• Women who do not want to participate in the study

• Women who are unable to give informed, written consent.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	STHF, Kvinneklinikken, Fertilitetsklinikken Sor	Porsgrunn	Telemark	Norway	3901

Sponsors and Collaborators

• Sykehuset Telemark

Investigators

• Principal Investigator: Jarl A Kahn, Dr. med, STHF, Kvinneklinikken, Fertilitetsklinikken Sor

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00518141
• Other Study ID Numbers: S-06085 (REK)
• First Posted: Aug 20, 2007
• Last Update Posted: Jul 21, 2011
• Last Verified: Jul 1, 2011

• Additional relevant MeSH terms: Aspirin; Salicylic Acid; Salicylates

Study Results

No Results Posted as of Jul 21, 2011